A menopause MRI study found no significant grey-matter loss in women changing stages. Learn how the finding fits alongside brain-fog concerns.
On 2026-10-26, Vilnius University reported that a study published in Nature Communications found no significant reduction in total grey-matter volume among women who moved from premenopause to postmenopause during observation. The university described the result as unexpected, with declines seen in women who remained in either menopausal stage.
Vilnius University reports that the researchers began with an expectation about sex hormones and brain structure. They anticipated that falling sex hormones during menopause would be linked to changes in the opposite direction from those seen during adolescence and pregnancy. The findings instead pointed to a more complex relationship.
That distinction matters when describing what this study updates. The university account presents a challenge to a research expectation, not an announcement that clinicians should replace an existing treatment protocol. Calling the finding a reversal of medical advice would give it a different meaning from the one reported.
For readers, the useful shift is in the story being told about midlife. The study offers a reason to question a simple account in which menopause and age-related structural decline follow a single predictable course. It invites a more precise question: which aspect of the brain changed in which group?
Vilnius University reports that the study analysed brain-imaging data across adolescence, pregnancy and menopause. Its account sets out several findings that help place the menopause result in context:
These results need to be read within a clear set of boundaries. “No significant reduction” is a finding about a measured group over an observation period. It is not a guarantee of no change in every participant, proof that menopause protects the brain or evidence that brain ageing stops.
Vilnius University’s account does not supply the menopause subgroup size or full statistical details. It also does not give enough information to assess statistical power, scan timing relative to menopause or whether the comparison groups were otherwise comparable. Those missing details limit how closely readers can assess the comparison.
The same account does not establish that menopause caused the pattern or that hormones explain it. Biological mechanisms remain poorly understood. It does not report whether this pattern corresponded to changes in everyday memory, attention or cognitive performance.
Taken together, these boundaries keep the finding at the level of group research rather than a personal health forecast. Grey-matter volume is a structural imaging measure, not a direct assessment of an individual woman’s daily functioning. Refemina’s discussion of how brain structure is studied during menopause offers related background on this distinction.
In separate coverage published on 2026-10-22, Contemporary OB/GYN reported Pauline M. Maki’s clinical perspective from the Menopause Society’s 2026 annual meeting. The neurologist and researcher estimated that 40% to 60% of women experience brain fog or forgetfulness during the menopause transition.
That estimate belongs to the meeting coverage, not to the MRI study. Keeping those accounts separate allows each to address its own question. One concerns reported cognitive experiences and clinical care; the other concerns measured brain structure.
Maki said hot flashes and night sweats, sleep disruption and mood changes may affect brain health and cognitive performance. She described an approach that normalizes brain-fog complaints while distinguishing menopause-related changes from dementia-related changes. Her clinical approach also includes addressing vasomotor symptoms, disrupted sleep and mood changes.
This is practical context for a woman who finds her concentration troubling. It makes room for a conversation about the wider symptom picture rather than reducing the concern to one explanation. Refemina’s coverage of the relationship between menopausal symptoms and sleep addresses a related part of that conversation.
Maki’s reported approach supports discussing troubling memory or concentration changes with a healthcare professional. The useful starting point is the experience being reported, alongside other symptoms that may be present. A woman’s concern deserves attention in its own right.
A consultation can make space for questions such as:
These questions reflect the clinical priorities Maki described: taking the complaint seriously, distinguishing menopause-related concerns from dementia-related changes, and addressing symptoms involving hot flashes or sleep and mood. They are discussion points for qualified care rather than a way to diagnose the cause of a concern independently.
Normalizing a complaint should mean making it discussable, not telling a woman to put up with it. That is an editorial distinction worth holding onto. Reassurance is more useful when it leaves room for a proper conversation about the experience and its context.
The practical focus therefore stays with understanding the concern and discussing relevant symptoms. It does not require a woman to adopt a particular story about what menopause ought to feel like. The research can make that conversation more informed without making it less personal.
Vilnius University’s account quotes Prof. Grikšienė as saying that age-related structural changes may “temporarily slow down or take a different course” during the menopausal transition. She also stressed that the result does not mean nothing is happening in the brain.
Her interpretation frames menopause as a possible distinct phase of brain adaptation. The word “adaptation” is useful here because it shifts the discussion away from treating every structural difference as a loss that must be corrected. It offers a research perspective rather than a new expectation for how every woman should feel.
There is a difference between a calmer explanation and a dismissive one. A calmer explanation allows the MRI finding to complicate a decline narrative while clinical attention stays with the woman’s reported experience. It does not ask her to choose between taking the research seriously and acknowledging that something in her daily life feels different.
Going forward, this research should support more precise explanations of menopausal brain changes while keeping clinical attention on the symptoms women report.
Questions about brain fog belong in conversations between women and qualified healthcare professionals; Refemina supplies editorial context around the science. Where health coverage reduces a cognitive concern to a supplement or hormone opportunity, its research-led approach helps readers separate credible evidence from promotional claims and understand hormonal change within the wider experience of midlife.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources